Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button

FAQs

FAQs
Types of Early DMPK Studies
Protein binding: plasma, brain tissue, microsomal protein, FBS; Erythrocyte /plasma partition ratio ​Optimization permeability and transshipment: Caco - 2. MDCK - MDR1 / BCRP, OATs/OCTs/OATPs
Learn more
The Key of Stability Studies in Phase I and Phase III Clinical Trials
Phase I clinical ◆ Stability data should support be able to support the formulation to meet the requirements during the clinical study
Learn more
Differencese of Quality Research Between Phase Ⅰ and Ⅲ?
Phase 1 clinical No need for comprehensive and complete validation of analytical methods (need for specificity, sensitivity, etc.)
Learn more
Classification Based on the Structural Form of Bispecific Antibodies
IgG-like BsAb has an Fc part and Fc-mediated effect functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP). The Fc part of the antibody is helpful for purification and improves its solubility and stability in the later stages.
Learn more
Types of Bispecific Antibodies
According to different structures, bispecific antibody structures can be divided into two main categories: bispecific antibodies with Fc fragment (IgG-like bispecific antibody) and bispecific antibodies without Fc fragment (non-IgG-like bispecific antibody).
Learn more
How to Optimize Oral Bioavailability in the Drug Discovery?
1) Understanding the structural boundaries associated with oral absorption 2) Identifying/determining the cause of poor oral bioavailability within a compound family
Learn more
Importance of Pilot Scale-up
The pilot scale is generally a production activity where the process exceeds the kilogram level for the first time, and there are various uncertain factors.
Learn more
What is Ideal Synthetic Route?
Economic and reasonable • Simple synthesis route with few steps • FDA: The proposed starting material should react multiple steps apart from the final intermediate of the API • The raw materials are easy to obtain and stable. • Intermediates are easily separated and stable. • It is easy to operate and reaches the medicinal standard after separation and purification. • High yield, low cost and maximum economic benefit
Learn more
Characteristics of an Excellent API Synthesis Process
Feasibility,Controllability,Rationality
Learn more
What is the Goal of Process Development?
The goal of API manufacturing process development is to establish a commercial manufacturing process capable of consistently producing the API of expected quality.
Learn more